Lowest Price Guaranteed
Pages
306
Last Updated
July 2026
View Count
26719
The global therapeutic vaccines market, valued at USD 6.7 billion in 2025, is projected to reach USD 11.0 billion in 2026 and USD 86.8 billion by 2035, representing a CAGR of 25.8% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Unlike prophylactic vaccines that are designed and administered as a precautionary measure to prevent the occurrence of a disease, researchers have developed therapeutic vaccines intended to alleviate the suffering of patients already infected with the disease. Therapeutic vaccines are not as efficacious as prophylactic vaccines; however, they demonstrate safety, specificity and a long-lasting response across various clinical conditions. These vaccines help the immune system recognize a foreign agent and are primarily being developed for viral infections and different types of cancer.
Additionally, individuals affected by chronic infections who cannot produce enough efficient antibodies can be treated through such vaccines. Notably, only one melanoma vaccine, Imlygic® (T-VEC), is currently FDA-approved. In addition, over 400 cancer vaccine trials are currently active worldwide, with 300+ cancer vaccine drugs in development for various oncological, infectious, hepatological, neurological, and autoimmune disorders. ,
Extensive research is being conducted to improve the overall stability of these therapeutic formulations, and a variety of adjuvants are also being discovered for the development of more versatile vaccine formulations. For instance, in January 2026, Moderna and Merck collectively announced the sustained benefit of their experimental personalized vaccines used in combination with Keytruda for the treatment of skin cancer. Notably, the treatment is likely to reduce the risk of recurrence or death by 49% after five years. Further, researchers are also investigating the potential of these vaccines against other chronic disease conditions, including hypertension and autoimmune disorders.
Over the last few years, this segment of the industry has witnessed substantial partnership activity and investment from various private and public sector investors / investment funds, which have extended financial support to the organizations engaged in R&D. Driven by encouraging clinical trial results, increasing adoption of these vaccines for treating various clinical conditions and investment in R&D, the therapeutic vaccines market is poised to witness noteworthy market growth during the forecast period.
Based on the research, we have segmented the Therapeutic Vaccines Market into type of vaccine, method of vaccine composition, type of therapy, therapeutic area, route of administration and key geographical regions.
By Type of Vaccine
By Method of Vaccine Composition
By Type of Therapy
By Therapeutic Area
By Route of Administration
By Key Geographical Regions
Recently, there has been a clear shift in the vaccine landscape toward next-generation neoantigen mRNA vaccines. This shift is driven by advances in genomic sequencing, bioinformatics, and personalized medicine approaches. Unlike earlier cancer vaccines, these novel therapies are designed to target patient-specific tumor neoantigens with greater precision, thereby enhancing immune response and improving therapeutic outcomes. The growing focus on individualized cancer treatment, coupled with increasing clinical success of mRNA-based platforms, is expected to accelerate the adoption of next-generation neoantigen vaccines. As a result, this emerging trend is anticipated to create significant growth opportunities for market stakeholders by expanding the clinical application of cancer immunotherapies, attracting strategic investments, and driving innovation across the neoantigen vaccine development landscape.
Driven by the rising cancer prevalence, expanding immunotherapy applications across treatment settings and increasing chronic disease burden, the market is poised to grow significantly in the near future.
Dr. Thomas Marron (Associate Director for Translational Research, Tisch Comprehensive Cancer Center), stated that, “Many of the most promising vaccines being developed today are intended for the adjuvant setting, which means after surgery. When a tumor (whether lung cancer or melanoma) is removed, microscopic bits may have already spread elsewhere in the body, such as the brain, liver, bones, or other parts of the lung. Adjuvant therapy targets these residual cells. Sometimes this involves chemotherapy or immunotherapy.”
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:
This segment highlights the distribution of market value for the therapeutic vaccines market across various types of vaccines, such as peptide vaccines, antigen vaccines, DNA vaccines and dendritic vaccines.
Currently, peptide vaccines hold the largest share of the market due to their high specificity, favorable safety profile, and broad applicability in cancer immunotherapy and infectious disease treatment. These vaccines utilize selected antigenic peptides to stimulate targeted immune responses against specific disease-associated markers, thereby minimizing the risk of off-target effects. Further, their relatively simple design, ease of synthesis, manufacturing scalability, and stability compared to more complex vaccine platforms have contributed towards their widespread research and clinical adoption.
Further, the market for DNA vaccines is expected to grow at a significant pace during the forecast period owing to advancements in genetic engineering technologies and the increasing demand for next-generation vaccine platforms. DNA vaccines also offer several advantages, including rapid design and development, manufacturing flexibility, improved stability, and the ability to induce both humoral and cellular immune responses.
Furthermore, rising investments in genomic medicine, expanding clinical trial activity, and increasing interest in personalized and precision immunotherapies are expected to drive substantial growth of the DNA vaccines segment during the forecast period.
| Type of Vaccine | Key Advantages | Limitations | Immunogenicity & Efficacy Profile |
| Peptide Vaccines | High specificity & safety profile, Minimal risk of autoimmunity or contamination, and Stable and well-characterized | Poor inherent immunogenicity, HLA-restriction, and short half-life & rapid degradation | Moderate (stronger with adjuvants / and in combination) |
| Antigen Vaccines | Targeted to specific disease markers and strong safety record | Limited to known antigens and less effective against heterogeneous tumors | Low to Moderate (for humoral and cellular responses) |
| DNA Vaccines | Stable, easy to manufacture & store, Can encode multiple antigens, and Induces both humoral & cellular immunity | Lower immunogenicity in humans, Potential integration concerns, and Delivery efficiency challenges | Moderate to high (enhanced with electroporation / vectors) |
| Dendritic Cells | Highly personalized & potent antigen presentation and strong T-cell activation & long-term immunity | Complex, patient-specific manufacturing, Logistical challenges, and Scalability issues | High (best-in-class for specific immune priming and durable responses) |
This segment highlights the distribution of market value for the therapeutic vaccines market across various methods of vaccine composition, such as autologous vaccines and allogeneic vaccines.
Currently, autologous vaccines hold the largest share of the market due to their personalized approach and ability to generate highly specific immune responses using a patient's own cells or tumor-derived antigens. These vaccines are particularly prominent in cancer immunotherapy, where they are designed to target unique tumor characteristics, thereby enhancing therapeutic efficacy while minimizing the risk of immune rejection. Further, the growing emphasis on precision medicine, coupled with increasing clinical evidence supporting the effectiveness of individualized treatment strategies, has driven the adoption of autologous vaccine platforms.
Notably, the allogeneic vaccines segment is expected to grow at a significant pace during the forecast period owing to its potential to provide scalable, standardized, and cost-effective therapeutic vaccine solutions. Unlike autologous vaccines, allogeneic vaccines are developed using donor-derived cells or antigens, enabling large-scale manufacturing and broader patient accessibility.
Additionally, increasing demand for more accessible cancer immunotherapies, growing clinical trial activity, and ongoing efforts to reduce production complexity and treatment costs are expected to drive substantial growth in the allogeneic vaccines segment during the forecast period.
This segment highlights the distribution of market value for the therapeutic vaccines market across various types of therapies, such as monotherapies and combination therapies.
Currently, monotherapies hold the largest share of the market due to their established clinical use, simplified treatment protocols, and well-characterized safety and efficacy profiles. Further, therapeutic vaccines (administered as standalone treatments) are often preferred in early-stage clinical applications and specific patient populations because they reduce treatment complexity and minimize the risk of adverse interactions associated with combination regimens. In addition, monotherapies typically face less complicated regulatory pathways and are easier to evaluate in clinical trials, which has supported their widespread adoption.
The combination therapies segment is expected to grow at a significant pace during the forecast period owing to the increasing recognition that therapeutic vaccines can achieve enhanced clinical outcomes when used alongside other treatment modalities such as immune checkpoint inhibitors, targeted therapies, chemotherapy, or cell-based therapies. These combinations have the potential to generate stronger and more durable immune responses, overcome tumor immune evasion mechanisms, and improve overall treatment efficacy. Growing clinical evidence supporting synergistic effects, increasing investment in combination-based immuno-oncology research, and a robust pipeline of clinical trials are accelerating the adoption of this approach.
This segment highlights the distribution of market value for the therapeutic vaccines market across various therapeutic areas, such as oncological disorders, infectious diseases, autoimmune disorders and others.
Oncological disorders hold the largest share of the market due to the growing burden of cancer worldwide and the increasing adoption of therapeutic vaccines as a promising immunotherapy approach. Cancer therapeutic vaccines are designed to stimulate the immune system to recognize and target tumor-specific antigens, offering a more precise and potentially durable treatment strategy when compared to conventional therapies. Significant investments in cancer research, a robust pipeline of therapeutic vaccine candidates, and the rising integration of vaccines with other immuno-oncology treatments have accelerated their clinical development and commercialization.
The infectious diseases segment is expected to grow at a significant pace during the forecast period owing to the increasing focus on developing these vaccines for chronic and difficult-to-treat infections, including viral, bacterial, and emerging infectious diseases. Advances in vaccine technologies, such as DNA, RNA, and vector-based platforms, are enabling the development of novel therapeutic approaches aimed at enhancing immune responses and improving disease management.
Additionally, the expanding prevalence of chronic infectious diseases and the need for long-term treatment solutions that can complement or reduce reliance on conventional antimicrobial therapies are expected to support the rapid expansion of the infectious diseases segment during the forecast period.
This segment highlights the distribution of market value for the therapeutic vaccines market across various routes of administration, such as intradermal route, intramuscular route, subcutaneous route, intranasal route, oral route and others.
Currently, intradermal route holds the largest share of the market due to its ability to elicit strong immune responses using relatively small doses of antigens. The dermal layer of the skin contains a high concentration of antigen-presenting cells, such as dendritic cells and macrophages, which play a critical role in initiating immune responses. This enhanced immunogenicity makes intradermal administration particularly attractive for therapeutic vaccines targeting cancer and infectious diseases.
Additionally, advances in microneedle technologies, specialized delivery devices, and dose-sparing strategies have improved the feasibility and effectiveness of intradermal vaccine administration. The growing adoption of immunotherapy-based treatments and increasing research into skin-targeted vaccine delivery have further contributed to the dominant position of the intradermal route in the therapeutic vaccines market.
The intranasal segment is expected to grow at a significant pace during the forecast period owing to its non-invasive nature and ability to induce both systemic and mucosal immune responses. Intranasal administration directly targets the mucosal surfaces, which serve as the primary entry point for many pathogens, thereby enhancing protective immunity and potentially improving therapeutic outcomes.
Furthermore, rising research activities focused on respiratory infections, cancer immunotherapy, and novel vaccine formulations, coupled with efforts to improve patient compliance and accessibility, are expected to drive substantial growth of the intranasal segment during the forecast period.
According to our projections, North America is likely to capture the majority of the therapeutic vaccines market share in the current year. This can be attributed to its advanced healthcare infrastructure, strong biotechnology and pharmaceutical industry presence, and substantial investments in immunotherapy research and development.
The region has been at the forefront of developing therapeutic vaccines for cancer, infectious diseases, and other chronic conditions, supported by a robust clinical trial ecosystem and favorable regulatory pathways. Additionally, the high prevalence of cancer and other chronic diseases, increasing adoption of personalized medicine, and widespread availability of advanced healthcare services have accelerated the adoption of therapeutic vaccine technologies.
The market in Asia-Pacific is likely to grow at the highest CAGR during the forecast period. This is due to rising healthcare expenditure, expanding biopharmaceutical research capabilities, and increasing prevalence of cancer and infectious diseases across countries such as China, India, Japan, and South Korea. Growing government support for biotechnology innovation, improving healthcare infrastructure, and increasing investments in vaccine research and development are creating favorable conditions for market expansion.
| Key Report Attribute | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 11.0 Billion | |
| Market Size 2035 | $ 86.8 Billion | |
| CAGR (Till 2035) | 25.8% | |
| Segments Covered |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |